Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results